With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.
Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute, explains the goals and patient population included in the EMPACT-MI trial.
Presented at the European Society of Cardiology (ESC) Congress 2023, EMPACT-MI is testing the safety and benefit of empagliflozin to reduce heart failure hospitalization or all-cause mortality in patients post myocardial infarction (MI).
Transcript
Can you give our audience an overview of your presentation on the EMPACT-MI trial?
There has been really no therapy that has shown risk reduction in post-MI heart failure development. We do know that once you develop heart failure, your 5-year mortality risk equals or exceeds about 50%, so anything to prevent heart failure is really important and myocardial infarction is one of the biggest risk factors. The data would suggest—epidemiologic data—that a quarter to a third of the patients post-MI develop heart failure, so prevention of heart failure is really, really important.
SGLT2 inhibitors have been shown to prevent heart failure in patients with CKD [chronic kidney disease] and diabetes, and MI patients are sort of an enriched population, but (A) we need to prove it, but (B) there are safety concerns also. The post-MI patients get procedures, an [intravenous] contrast, a new RAAS [renin-angiotensin-aldosterone system] inhibitor, a new MRA [mineralocorticoid receptor antagonist], and now SGLT2 inhibitor, so we need to see what the safety and what the benefit profile is.
That was being tested in the EMPACT-MI trial, a large trial, 6000 patients, about three-fourths STEMI [ST-elevation MI patients] and about one-fourth non-STEMI patients enriched for heart failure. So either new onset [MI], drop in EF [ejection fraction], or signs or symptoms of congestion. People with history of heart failure [prior to MI] were excluded. The trial has completed enrollment, is in the follow-up phase, and anxiously awaiting results and we'll get the results hopefully pretty soon in the next few months.
This transcript has been lightly edited for clarity.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More